Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial

R. Modi, K. R. Amico, A. Knudson, A. O. Westfall, Jeanne C Keruly, H. M. Crane, E. B. Quinlivan, C. Golin, J. Willig, A. Zinski, Richard D Moore, S. Napravnik, Bryan M Lau, M. S. Saag, M. J. Mugavero

Research output: Contribution to journalArticle

Abstract

During the initial year of HIV diagnosis, while patients are often overwhelmed adjusting to this life changing diagnosis, they must develop self-care behaviors for attending regular medical care visits and antiretroviral therapy (ART) adherence to achieve and sustain viral suppression (VS). Maintaining “HIV adherence” and integrating it into one's daily life is required to sustain VS over time. The HIV care continuum or “treatment cascade,” an epidemiological snapshot of the national epidemic in the United States (US), indicates that a minority of persons living with HIV (PLWH) have achieved VS. Little evidence exists regarding the effects of interventions focusing on PLWH newly initiating outpatient HIV care. An intervention that focuses on both retention in care and ART adherence skills delivered during the pivotal first year of HIV care is lacking. To address this, we developed a theory-based intervention evaluated in the Integrating Engagement and Adherence Goals upon Entry (iENGAGE) study, a National Institute of Allergy and Infectious Diseases (NIAID) funded randomized behavioral intervention trial. Here we present the study objectives, design and rationale, as well as the intervention components, targeting rapid and sustained VS through retention in HIV care and ART adherence during participants' first year of HIV care. The primary outcome of the study is 48-week VS (<200 c/mL). The secondary outcomes are retention in care, including HIV visit adherence and visit constancy, as well as ART adherence.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalContemporary Clinical Trials
Volume69
DOIs
StatePublished - Jun 1 2018

Fingerprint

HIV
National Institute of Allergy and Infectious Diseases (U.S.)
Therapeutics
Continuity of Patient Care
Ambulatory Care
Self Care
Outcome Assessment (Health Care)

Keywords

  • Adherence
  • Behavioral intervention
  • iENGAGE
  • New to HIV care
  • Retention in care
  • Viral load

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care : Rationale and design of iENGAGE intervention trial. / Modi, R.; Amico, K. R.; Knudson, A.; Westfall, A. O.; Keruly, Jeanne C; Crane, H. M.; Quinlivan, E. B.; Golin, C.; Willig, J.; Zinski, A.; Moore, Richard D; Napravnik, S.; Lau, Bryan M; Saag, M. S.; Mugavero, M. J.

In: Contemporary Clinical Trials, Vol. 69, 01.06.2018, p. 48-54.

Research output: Contribution to journalArticle

Modi, R, Amico, KR, Knudson, A, Westfall, AO, Keruly, JC, Crane, HM, Quinlivan, EB, Golin, C, Willig, J, Zinski, A, Moore, RD, Napravnik, S, Lau, BM, Saag, MS & Mugavero, MJ 2018, 'Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial', Contemporary Clinical Trials, vol. 69, pp. 48-54. https://doi.org/10.1016/j.cct.2018.03.003
Modi, R. ; Amico, K. R. ; Knudson, A. ; Westfall, A. O. ; Keruly, Jeanne C ; Crane, H. M. ; Quinlivan, E. B. ; Golin, C. ; Willig, J. ; Zinski, A. ; Moore, Richard D ; Napravnik, S. ; Lau, Bryan M ; Saag, M. S. ; Mugavero, M. J. / Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care : Rationale and design of iENGAGE intervention trial. In: Contemporary Clinical Trials. 2018 ; Vol. 69. pp. 48-54.
@article{e5ad9817d1f24a408d4aa608676641bd,
title = "Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial",
abstract = "During the initial year of HIV diagnosis, while patients are often overwhelmed adjusting to this life changing diagnosis, they must develop self-care behaviors for attending regular medical care visits and antiretroviral therapy (ART) adherence to achieve and sustain viral suppression (VS). Maintaining “HIV adherence” and integrating it into one's daily life is required to sustain VS over time. The HIV care continuum or “treatment cascade,” an epidemiological snapshot of the national epidemic in the United States (US), indicates that a minority of persons living with HIV (PLWH) have achieved VS. Little evidence exists regarding the effects of interventions focusing on PLWH newly initiating outpatient HIV care. An intervention that focuses on both retention in care and ART adherence skills delivered during the pivotal first year of HIV care is lacking. To address this, we developed a theory-based intervention evaluated in the Integrating Engagement and Adherence Goals upon Entry (iENGAGE) study, a National Institute of Allergy and Infectious Diseases (NIAID) funded randomized behavioral intervention trial. Here we present the study objectives, design and rationale, as well as the intervention components, targeting rapid and sustained VS through retention in HIV care and ART adherence during participants' first year of HIV care. The primary outcome of the study is 48-week VS (<200 c/mL). The secondary outcomes are retention in care, including HIV visit adherence and visit constancy, as well as ART adherence.",
keywords = "Adherence, Behavioral intervention, iENGAGE, New to HIV care, Retention in care, Viral load",
author = "R. Modi and Amico, {K. R.} and A. Knudson and Westfall, {A. O.} and Keruly, {Jeanne C} and Crane, {H. M.} and Quinlivan, {E. B.} and C. Golin and J. Willig and A. Zinski and Moore, {Richard D} and S. Napravnik and Lau, {Bryan M} and Saag, {M. S.} and Mugavero, {M. J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.cct.2018.03.003",
language = "English (US)",
volume = "69",
pages = "48--54",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care

T2 - Rationale and design of iENGAGE intervention trial

AU - Modi, R.

AU - Amico, K. R.

AU - Knudson, A.

AU - Westfall, A. O.

AU - Keruly, Jeanne C

AU - Crane, H. M.

AU - Quinlivan, E. B.

AU - Golin, C.

AU - Willig, J.

AU - Zinski, A.

AU - Moore, Richard D

AU - Napravnik, S.

AU - Lau, Bryan M

AU - Saag, M. S.

AU - Mugavero, M. J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - During the initial year of HIV diagnosis, while patients are often overwhelmed adjusting to this life changing diagnosis, they must develop self-care behaviors for attending regular medical care visits and antiretroviral therapy (ART) adherence to achieve and sustain viral suppression (VS). Maintaining “HIV adherence” and integrating it into one's daily life is required to sustain VS over time. The HIV care continuum or “treatment cascade,” an epidemiological snapshot of the national epidemic in the United States (US), indicates that a minority of persons living with HIV (PLWH) have achieved VS. Little evidence exists regarding the effects of interventions focusing on PLWH newly initiating outpatient HIV care. An intervention that focuses on both retention in care and ART adherence skills delivered during the pivotal first year of HIV care is lacking. To address this, we developed a theory-based intervention evaluated in the Integrating Engagement and Adherence Goals upon Entry (iENGAGE) study, a National Institute of Allergy and Infectious Diseases (NIAID) funded randomized behavioral intervention trial. Here we present the study objectives, design and rationale, as well as the intervention components, targeting rapid and sustained VS through retention in HIV care and ART adherence during participants' first year of HIV care. The primary outcome of the study is 48-week VS (<200 c/mL). The secondary outcomes are retention in care, including HIV visit adherence and visit constancy, as well as ART adherence.

AB - During the initial year of HIV diagnosis, while patients are often overwhelmed adjusting to this life changing diagnosis, they must develop self-care behaviors for attending regular medical care visits and antiretroviral therapy (ART) adherence to achieve and sustain viral suppression (VS). Maintaining “HIV adherence” and integrating it into one's daily life is required to sustain VS over time. The HIV care continuum or “treatment cascade,” an epidemiological snapshot of the national epidemic in the United States (US), indicates that a minority of persons living with HIV (PLWH) have achieved VS. Little evidence exists regarding the effects of interventions focusing on PLWH newly initiating outpatient HIV care. An intervention that focuses on both retention in care and ART adherence skills delivered during the pivotal first year of HIV care is lacking. To address this, we developed a theory-based intervention evaluated in the Integrating Engagement and Adherence Goals upon Entry (iENGAGE) study, a National Institute of Allergy and Infectious Diseases (NIAID) funded randomized behavioral intervention trial. Here we present the study objectives, design and rationale, as well as the intervention components, targeting rapid and sustained VS through retention in HIV care and ART adherence during participants' first year of HIV care. The primary outcome of the study is 48-week VS (<200 c/mL). The secondary outcomes are retention in care, including HIV visit adherence and visit constancy, as well as ART adherence.

KW - Adherence

KW - Behavioral intervention

KW - iENGAGE

KW - New to HIV care

KW - Retention in care

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=85046114466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046114466&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2018.03.003

DO - 10.1016/j.cct.2018.03.003

M3 - Article

C2 - 29526609

AN - SCOPUS:85046114466

VL - 69

SP - 48

EP - 54

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -